These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 811288)

  • 1. The K-test (trypsin clotting time) in coumarin treated patients and in congenital deficiencies and abnormalities of the prothrombin complex.
    Girolami A; Brunetti A; Patrassi G; Cafiero F
    Blut; 1975 Nov; 31(5):291-8. PubMed ID: 811288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Congenital bleeding disorders of the vitamin K-dependent clotting factors.
    Girolami A; Scandellari R; Scapin M; Vettore S
    Vitam Horm; 2008; 78():281-374. PubMed ID: 18374200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromogenic substrate (S-2238) prothrombin assay in prothrombin deficiencies and abnormalities. Lack of identity with clotting assays in congenital dysprothrombinemias.
    Girolami A; Patrassi G; Toffanin F; Saggin L
    Am J Clin Pathol; 1980 Jul; 74(1):83-7. PubMed ID: 7395819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotest mixing experiments in congenital coagulation disorders of the prothrombin complex and in coumarin treated patients. An additional evidence against the presence of an inhibitor in the latter.
    Girolami A; Patrassi O; Cella G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1977; 104(3):463-70. PubMed ID: 72033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normotest--thrombotest discrepancy in congenital coagulation disorders of the prothrombin complex and in coumarin-treated patients: a nonspecific phenomenon.
    Girolami A; Brunetti A; Patrassi GM
    Am J Clin Pathol; 1977 Jan; 67(1):57-60. PubMed ID: 831455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glass activation-induced decrease or disappearance of normotest-thrombotest discrepancy in congenital coagulation disorders of the prothrombin complex.
    Girolami A; Patrassi G; Fabris F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1977; 104(2):283-93. PubMed ID: 69593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commercial variants of the prothrombin time test as a screening test of acquired coagulation factor II, VII, and X deficiencies in dogs.
    Mischke R
    Res Vet Sci; 2002 Oct; 73(2):165-70. PubMed ID: 12204636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of a chromogenic prothrombin time with clotting prothrombin time in the assessment of clinical coagulation deficiencies.
    Francis CW; Malone JE; Marder VJ
    Am J Clin Pathol; 1985 Dec; 84(6):724-9. PubMed ID: 4072967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taipan viper venom and chromogenic substrate (chromozym Th). Prothrombin assay. No sensitivity to coumarin-induced prothrombin.
    Girolami A; Petrassi G; Cella G; Saltarin P
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(6):822-30. PubMed ID: 6176507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical use of a test for determination of coagulation factors II, X and VII].
    Cascino A; Cangiano C; Attili AF
    Minerva Med; 1975 Aug; 66(55):2743-9. PubMed ID: 1161171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a prothrombin time optimized for the dog on plasmas with defined coagulation factor deficiency due to coumarin intoxication.
    Mischke R
    Zentralbl Veterinarmed A; 1995 Nov; 42(9):589-99. PubMed ID: 8822195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Congenital deficiency of factor VII in a canine family].
    Noguchi M; Fujii T; Michizono A
    Jikken Dobutsu; 1987 Oct; 36(4):423-30. PubMed ID: 3436375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hepato-quick--a new thromboplastin time system: a comparison with normotest and thrombotest (author's transl)].
    Fischer M; Falkensammer C
    Wien Klin Wochenschr; 1974 Oct; 86(19):577-83. PubMed ID: 4432516
    [No Abstract]   [Full Text] [Related]  

  • 14. [Mixing test for prolonged clotting time: clinical availability and problems].
    Uchiba M; Ando Y
    Rinsho Byori; 2009 Oct; 57(10):1004-12. PubMed ID: 19928499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COAGULATION AND FIBRINOLYSIS IN INJURED PATIENTS.
    INNES D; SEVITT S
    J Clin Pathol; 1964 Jan; 17(1):1-13. PubMed ID: 14103515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromogenic substrate (S-2222) factor X assays in the follow-up of coumarin treated patients. No advantage over prothrombin time and/or thrombotest.
    Girolami A; Saggin L; Gazzetta R; Saltarin P
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(4):610-6. PubMed ID: 6170557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A "new" congenital haemorrhagic condition due to the presence of an abnormal factor X (factor X Friuli): study of a large kindred.
    Girolami A; Molaro G; Lazzarin M; Scarpa R; Brunetti A
    Br J Haematol; 1970 Aug; 19(2):179-92. PubMed ID: 4989292
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical implications of clotting screens.
    Thorell SE; Nash MJ; Thachil J
    Int J Lab Hematol; 2015 Feb; 37(1):8-13. PubMed ID: 24636194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COUMARIN THERAPY. PROTHROMBIN ACTIVITY AFTER TERMINATION OF TREATMENT.
    REILLY EB; GOODMAN JR; WARNER GF
    Calif Med; 1963 Oct; 99(4):234-5. PubMed ID: 14051485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prothrombin time sensitivity and specificity to mild clotting factor deficiencies of the extrinsic pathway: evaluation of eight commercial thromboplastins.
    Massignon D; Moulsma M; Bondon P; Debize G; Abidi H; Buttin T; Bon C; Pillonchery G; Coeur P
    Thromb Haemost; 1996 Apr; 75(4):590-4. PubMed ID: 8743184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.